Nigerians Scramble for Twice-Yearly HIV Prevention Injection
Nigerians have begun a frantic search for Lenacapavir, a newly introduced injectable for HIV prevention, ahead of its official nationwide rollout. Individuals, particularly those in “discordant” relationships where one partner is HIV-positive, are reportedly besieging health facilities and NGOs to secure the drug. The Federal Government has already received its first tranche of 11,520 doses, part of a planned 52,000-dose consignment, to be deployed across ten pilot locations. The official unveiling is scheduled for Tuesday, 24 March 2026.
Lenacapavir represents a seismic shift in Pre-Exposure Prophylaxis (PrEP). Unlike traditional daily pills, this long-acting injection is administered only twice a year. Clinical trials have shown that it offers nearly 100% protection against sexually acquired HIV. However, its sudden popularity has birthed a dangerous misconception. Many seekers mistakenly believe the injection is a cure for those already infected. Health officials are now racing to clarify that Lenacapavir is strictly for prevention and will not benefit those already living with the virus.
The initial rollout covers Akwa Ibom, Anambra, Benue, Cross River, Ebonyi, Gombe, Kano, Kwara, Lagos, and the FCT. Osun State has also recently been added to the pilot phase. In states like Anambra and Kwara, the drug has already been moved to designated general hospitals and specialist centres. High demand is not limited to the public; health workers are also lining up to receive the jab as a professional safeguard. Despite the enthusiasm, the drug remains unavailable in commercial pharmacies and must be administered by trained professionals at zero cost to the patient.
The Pharmaceutical Society of Nigeria (PSN) has urged the public to exercise caution in its excitement. While the World Health Organization (WHO) endorsed the drug in July 2025, the PSN insists that domestic regulatory protocols must be strictly followed. A dedicated committee is currently reviewing the integration of the injection into the national health system. There are also specific medical exclusions: for now, the Ministry of Health advises that pregnant women should not take the injection until further data is available.
For the two million Nigerians living with HIV, the arrival of this drug is a bittersweet milestone. While it cannot cure them, it offers a powerful shield for their loved ones and high-risk groups like sex workers and young adults. The National Agency for the Control of AIDS (NACA) views this as a critical tool for reaching the 2030 goal of epidemic control. If adherence to daily pills was the old barrier, Lenacapavir has effectively removed it with a single needle.
As the 24 March launch approaches, the government’s primary challenge will be managing expectations. With only 52,000 doses expected for the entire year, the supply will be dwarfed by the demand of a population of over 200 million. Priority will be given to the most vulnerable, but the “scramble” suggests that many will be left waiting. The success of this pilot will determine how quickly the government scales up to a truly national distribution network.